Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

141. A systematic review of pertuzumab, trastuzumab and docetaxel for patients with HER2-positive breast cancer

A systematic review of pertuzumab, trastuzumab and docetaxel for patients with HER2-positive breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

142. Clinical value of capecitabine addition to standard adjuvant chemotherapy in early triple negative breast cancer: survival outcome from a meta-analysis of randomized controlled trials

Clinical value of capecitabine addition to standard adjuvant chemotherapy in early triple negative breast cancer: survival outcome from a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

143. Association of night shift work and breast cancer incidence: evidences from an updated meta-analysis of prospective cohort studies

Association of night shift work and breast cancer incidence: evidences from an updated meta-analysis of prospective cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

144. Small molecule biomarkers for the early detection of breast cancer: a systematic review

Small molecule biomarkers for the early detection of breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

145. Comparative efficacy, safety and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Comparative efficacy, safety and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

146. Comparative clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a network meta-analysis of randomized controlled trials

Comparative clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

147. Clinical efficacy of weekly cisplatin chemotherapy (WCCT) for treatment of patients with breast cancer (BC): a systematic review protocol

Clinical efficacy of weekly cisplatin chemotherapy (WCCT) for treatment of patients with breast cancer (BC): a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

148. Effects of exercise and wellness programming for women receiving or have received treatment for breast cancer: a systematic review

Effects of exercise and wellness programming for women receiving or have received treatment for breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

149. Effect of vitamin D supplementation on risk of breast cancer and breast density: a systematic review and meta-analysis of randomized controlled trials

Effect of vitamin D supplementation on risk of breast cancer and breast density: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

150. Cost-effectiveness analysis of analog mammography compared to digital mammography in screening of women with breast cancer: a systematic review

Cost-effectiveness analysis of analog mammography compared to digital mammography in screening of women with breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

151. Criterion validation of screening tools for early detection of oral, breast and cervical cancers: systematic review and meta-analysis

Criterion validation of screening tools for early detection of oral, breast and cervical cancers: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

152. Chinese medicine for immunological functions in women with breast cancer or a history of breast cancer [Cochrane protocol]

Chinese medicine for immunological functions in women with breast cancer or a history of breast cancer [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

153. Fluorescence imaging in breast cancer surgery: a systematic review

Fluorescence imaging in breast cancer surgery: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

154. Hormone receptor expression and molecular sub-types of breast cancer in the sub-Saharan Africa: a systematic review and meta-analysis

Hormone receptor expression and molecular sub-types of breast cancer in the sub-Saharan Africa: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

155. The adverse effects of trastuzumab-containing regimes as an adjuvant or neoadjuvant therapy in breast cancer: a piggy-back systematic review and network meta-analysis

The adverse effects of trastuzumab-containing regimes as an adjuvant or neoadjuvant therapy in breast cancer: a piggy-back systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

156. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer [Cochrane protocol]

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

157. The effect of exercise program on aromatase inhibitor induced by musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis

The effect of exercise program on aromatase inhibitor induced by musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

158. Results from different aerobic exercise protocol on cardiorespiratory fitness in breast cancer patients under chemotherapy: a systematic review and meta-analysis

Results from different aerobic exercise protocol on cardiorespiratory fitness in breast cancer patients under chemotherapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

159. Management of side-effects among women with breast cancer using adjuvant hormonal therapy: a systematic review of reviews

Management of side-effects among women with breast cancer using adjuvant hormonal therapy: a systematic review of reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

160. Prevalence of co-morbidity and survival among breast cancer patients - a systematic review

Prevalence of co-morbidity and survival among breast cancer patients - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO